CClinicalTrials.gg
TerminatedNCT04829058Updated Sep 11, 2026

GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study

An observational study in Pelvic Organ Prolapse, sponsored by Ethicon, Inc.. Terminated at 3 sites in 2 countries. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Ethicon, Inc. · Observational

Why this study was terminated
Change in business strategy
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
64
Ages
21 Years and older
Sex
Female
01

Study summary

The objective of this retrospective and prospective, single-arm, observational, multicenter, post-market study is to evaluate outcomes in women who underwent surgery for vaginal or uterine prolapse with a GYNEMESH PS Mesh.

02

Conditions studied

  • Pelvic Organ Prolapse

Browse trials for

Keywords

  • GYNECARE GYNEMESH® PS Nonabsorbable PROLENE® Soft Mesh
  • POP
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female subjects ≥ 21 years of age:

  • with a baseline diagnosis of apical vaginal or uterine prolapse;
  • who had laparotomic or laparoscopic sacrocolpopexy, including robotic-assisted, for apical vaginal or uterine prolapse within 7 years of enrolment;
  • where GYNEMESH PS Mesh was used as a bridging material, and;
  • who are willing and able to participate in prospective follow-up.

Inclusion criteria

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:

  1. Female subjects who had laparotomic or laparoscopic abdominal sacrocolpopexy, including robotic-assisted, for apical vaginal or uterine prolapse
  2. GYNEMESH PS Mesh was used as a bridging material according to the IFU.
  3. Able and willing to participate in follow-up
  4. Subject or authorized representative has signed the approved informed consent

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study:

  1. Subjects \< 21 years of age at the time of informed consent
  2. Subjects who had transvaginal approach for surgery
  3. Had undergone a uterus-sparing procedure (sacrohystero or sacrocervicopexy)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
64 participants (actual)
Patient registry
No

Interventions

  • DeviceIntervention

    There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.

05

What researchers measure

Primary outcomes

  1. Physical examination with Pelvic Organ Prolapse Quantification (POP-Q) Assessment CHange

    Objective cure of vaginal or uterine prolapse approximately 7 years after surgery, defined as POP-Q stage ≤2 at point C as determined with physical exam.

    Time frame: Post-surgery through study completion, approximately 7 yrs

Secondary outcomes

  1. Patient Global Impression of Improvement (PGI-I) or Patient Global Impression of Change (PGI-C) Questionnaire

    Time frame: Post-surgery through study completion, approximately 7yrs

  2. Pelvic Floor Distress Inventory (PFDI-20) Questionnaire

    Time frame: Post-surgery through study completion, approximately 7yrs

  3. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) or Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

    Time frame: Post-surgery through study completion, approximately 7yrs

06

Study locations

3 sites
  • Institute for Female Pelvic Medicine
    North Wales, Pennsylvania 19454, United States
  • UMPC
    Pittsburgh, Pennsylvania 15213, United States
  • Universitatsklinikum Tubingen
    Tübingen, Germany
07

References and documents

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04829058
Lead sponsor
Ethicon, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Nov 24, 2021
Primary completion
Jun 24, 2026
Completion
Jun 24, 2026
Last update
Sep 11, 2026

Study contacts

Martin Weisberg, MD
study director · Ethicon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion